Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide.
Clorox stock has recovered some ground in the short term, yet over the past five years shareholders have seen the share price decline about 23%, while current valuation checks still lean toward the shares looking expensive rather than like a clear bargain.
Over the past five years, Clorox has delivered a share price decline of about 23%, which raises questions about how much long term value recent gains are really adding for holders.
Management expects supply chain efficiencies from a new enterprise resource planning system, which can support margins and cash flows, although any execution issues or slower than expected productivity gains may limit how much value the market is willing to ascribe to these changes.
Clorox scores just 2 out of 6 on the broader valuation checks, which points to a stock that currently leans expensive rather than one that clearly screens as undervalued.
The issue now is whether Clorox's recent share price resilience is already pricing in the expected operational improvements or if there is still room for the valuation to improve from here.
Find out why Clorox's -7.2% return over the last year is lagging behind its peers.
The P/E ratio is a useful lens for Clorox because earnings tend to be a key focus for mature consumer products companies. Clorox currently trades on a P/E of about 22.0x, which is slightly above both the peer group average of 21.3x and the wider Household Products industry average of 17.6x.
The fair P/E ratio implied by the broader checks is 19.2x, so the current multiple sits a few turns higher than what would typically be expected given Clorox's profile. Recent optimism around supply chain gains from the new ERP system may help explain why the stock holds a premium, yet the gap to the fair P/E still points to investors paying up for that potential. On this framework, the market is assigning a richer valuation to Clorox than the fundamentals snapshot would usually support.
On the P/E multiple alone, Clorox stock screens as overvalued compared with both tailored fair value estimates and key peers.
See what the numbers say about this price — find out in our valuation breakdown.
Simply Wall St Narratives pick up where the Clorox valuation puzzle leaves off, by spelling out which assumptions about Clorox's future growth, margins and earnings would need to hold for the stock to be worth materially more or less than today's price, and they sit on the company's Community page. Each one treats fair value as a thesis about how the business might develop over time, so you can see how that view holds up as new information arrives.
Community narratives on Clorox are split, with one side seeing meaningful upside if execution lands, while the other argues most of that hope is already reflected in the price.
"The imminent end of the Glad JV with P&G will directly expand gross margins as Clorox fully internalizes profits from this high-volume segment..."
Read the full Bull Case to see why Clorox could be undervalued
Bear case: roughly fairly valued
"Clorox is experiencing sluggish category growth and faces continued uncertainty around consumer demand, with management acknowledging that expectations for category normalization and sustainable top-line improvements remain unclear..."
Read the full Bear Case to see why Clorox could be overvalued
Do you think there's more to the story for Clorox? Head over to our Community to see what others are saying!
Clorox stock still screens as overvalued on the current P/E based checks, so the burden of proof now sits with the execution of its supply chain and margin plans. The broader valuation framework looks cautious rather than supportive, which means the market is already paying up for improvement rather than assuming a turnaround is still to come. The key question from here is whether Clorox can deliver the margin and cash flow resilience that would justify holding that premium against both peers and its own recent track record.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include CLX.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]